Anti-PF4 immunothrombosis without proximate heparin or adenovirus vector vaccine exposure
Blood · 28.12.2023 · 142 (26) · 2305-2314
DOI: 10.1182/blood.2023022136 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood, erschienen am 28.12.2023. Verfasst von Linda Schönborn und 24 weiteren Autor:innen. Beteiligte Einrichtung: Institut für Transfusionsmedizin, Universitätsmedizin Greifswald, Greifswald, Germany. Hauptthemen laut MEDLINE: Thrombocytopenia, Antibodies, Thrombosis. Die Arbeit wurde bisher 73-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Platelet-activating anti-platelet factor 4 (PF4)/heparin antibodies and anti-PF4 antibodies cause heparin-induced thrombocytopenia (HIT) and vaccine-induced immune thrombocytopenia and thrombosis (VITT), respectively. Diagnostic and treatment considerations differ somewhat between HIT and VITT. We identified patients with thrombocytopenia and thrombosis without proximate heparin exposure or adenovirus-based vaccination who tested strongly positive by PF4/polyanion enzyme-immunoassays and negative/weakly positive by heparin-induced platelet activation (HIPA) test but strongly positive by PF4-induced platelet activation (PIPA) test (ie, VITT-like profile). We tested these patients by a standard chemiluminescence assay that detects anti-PF4/heparin antibodies found in HIT (HemosIL AcuStar HIT-IgG(PF4-H)) as well as a novel chemiluminescence assay for anti-PF4 antibodies found in VITT. Representative control sera included an exploratory anti-PF4 antibody-positive but HIPA-negative/weak cohort obtained before 2020 (n = 188). We identified 9 patients with a clinical-pathological profile of a VITT-like disorder in the absence of proximate heparin or vaccination, with a high frequency of stroke (arterial, n = 3; cerebral venous sinus thrombosis, n = 4), thrombocytopenia (median platelet count nadir, 49 × 109/L), and hypercoagulability (greatly elevated D-dimer levels). VITT-like serological features included strong reactivity by PIPA (aggregation <10 minutes in 9/9 sera) and positive testing in the novel anti-PF4 chemiluminescence assay (3/9 also tested positive in the anti-PF4/heparin chemiluminescence assay). Our exploratory cohort identified 13 additional patient sera obtained before 2020 with VITT-like anti-PF4 antibodies. Platelet-activating VITT-like anti-PF4 antibodies should be considered in patients with thrombocytopenia, thrombosis, and very high D-dimer levels, even without a proximate exposure to heparin or adenovirus vector vaccines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institut für Transfusionsmedizin, Universitätsmedizin Greifswald, Greifswald, Germany.
- Werfen, Lliçà d'Amunt, Barcelona, Spain.
- Department of Immunology, College of Medicine and Public Health, Flinders University and SA Pathology, Bedford Park, SA, Australia.
- Cardioangiology Center Bethanien Hospital, CCB Coagulation Center and CCB Coagulation Research Center, Frankfurt, Hessen, Germany.
- Institute for Transplantation Diagnostics and Cell Therapeutics, University Hospital Duesseldorf, Medical Faculty, Duesseldorf, Germany.
- Service and Central Laboratory of Hematology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
ORCID-Profile: Linda Schönborn, Jan Wesche, Sara Rovira Puig, Marta Palicio, Jing Jing Wang, Lorenzo Alberio, Christian Boehme, Matthias Endres, Theodore E Warkentin, Andreas Greinacher
Zitieren
APA
Schönborn, L., Esteban, O., Wesche, J., Dobosz, P., Broto, M., Puig, S. R., Fuhrmann, J., Torres, R., Serra, J., Llevadot, R., Palicio, M., Wang, J. J., Gordon, T. P., Lindhoff-Last, E., Hoffmann, T., Alberio, L., Langer, F., Boehme, C., Biguzzi, E., …, & Greinacher, A. (2023). Anti-PF4 immunothrombosis without proximate heparin or adenovirus vector vaccine exposure. Blood, 142(26), 2305-2314. https://doi.org/10.1182/blood.2023022136
Vancouver
Schönborn L, Esteban O, Wesche J, Dobosz P, Broto M, Puig SR, et al. Anti-PF4 immunothrombosis without proximate heparin or adenovirus vector vaccine exposure. Blood. 2023;142(26):2305-2314. doi:10.1182/blood.2023022136
BibTeX
@article{Schnborn2023,
author = {Schönborn, Linda and Esteban, Olga and Wesche, Jan and Dobosz, Paulina and Broto, Marta and Puig, Sara Rovira and Fuhrmann, Jessica and Torres, Raquel and Serra, Josep and Llevadot, Roser and Palicio, Marta and Wang, Jing Jing and Gordon, Tom Paul and Lindhoff-Last, Edelgard and Hoffmann, Till and Alberio, Lorenzo and Langer, Florian and Boehme, Christian and Biguzzi, Eugenia and Grosse, Leonie and Endres, Matthias and Liman, Thomas and Thiele, Thomas and Warkentin, Theodore E and Greinacher, Andreas},
title = {Anti-PF4 immunothrombosis without proximate heparin or adenovirus vector vaccine exposure},
journal = {Blood},
year = {2023},
volume = {142},
number = {26},
pages = {2305--2314},
doi = {10.1182/blood.2023022136}
}
EUVIMED